FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide

19 Mar 20264 min read0 views

GIST (Key Takeaways)

The U.S.
Food and Drug Administration today approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection for weight loss and long-term maintenance of weight loss for certain adult patients.

Clinical Editorial

FDA News Releases published a clinical update in Research Highlights on 19 Mar 2026. The item focuses on FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide. Open the detail page to review the full original feed content.